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Abstract
The nuclear transcription factor interferon regulatory
factor-1 (IRF-1) is a putative tumor suppressor, but the
expression and function of IRF-1 in esophageal adeno-
carcinoma (EA) remain unknown. We hypothesized
that IRF-1 expression was reduced or lost in EA and
that restoration of IRF-1 would result in the apoptosis
of EA cells in vitro and the inhibition of tumor growth
in vivo. Three EA cell lines were used to examine IRF-1
expression, IFN-; responsiveness, and the effects of
IRF-1 overexpression using a recombinant adenoviral
vector (Ad-IRF-1). All three EA cell lines produced IRF-1
protein following IFN-; stimulation, although IFN-; did
not induce cell death. In contrast, Ad-IRF-1 infection
resulted in high levels of IRF-1 protein and triggered
apoptosis in all three EA cell lines. Potential mecha-
nisms for the differential response to IFN-; versus
Ad-IRF-1—such as modulation of c-Met or extracellular
regulated kinase signaling, or altered expression of
IRF-2, Fas, or survivin—were investigated, but none
of these mechanisms can account for this observation.
In vivo administration of IRF-1 in a murine model of EA
modestly inhibited tumor growth, but did not lead to
tumor regression. Strategies aimed at increasing or
restoring IRF-1 expression may have therapeutic bene-
fits in EA.
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Introduction
The nuclear transcription factor interferon regulatory factor-1
(IRF-1) has been implicated as a potential tumor suppressor
[1–5]. IRF-1 is primarily induced by interferon gamma (IFN-g),
but is also induced by IFN-a, IFN-b, tumor necrosis factor-a,
retinoic acid, interleukin (IL) 1, and IL-6 [1,2,6–8]. IFN-g leads
to the activation of Janus kinase-1 (Jak-1) and Jak-2, result-
ing in the phosphorylation and dimerization of signal trans-
ducer and activator of transcription-1 (STAT-1). STAT-1
homodimers then translocate to the nucleus and bind to
promoter IFN-g activation site elements to initiate or suppress
the transcription of IFN-g–regulated genes such as IRF-1 [9].
IRF-1 subsequently binds to specific DNA sequences in sev-
eral promoters (IFN-stimulated response element) to initiate
the transcription of genes involved in mediating the antiviral,
immunomodulatory, antiproliferative, and apoptotic effects of
IFN-g signaling [2,10,11].
There have been few studies demonstrating the role of IRF-1
in the pathology and treatment of gastrointestinal malignancies
[5,12], and there have been no studies examining IRF-1 in eso-
phageal adenocarcinoma (EA). The incidence of EA is rising
more rapidly than any other tumor; currently, EA represents
the most common histologic type of esophageal cancer in
the United States [13–15]. Despite advances in diagnosis and
treatment, overall 5-year survival remains approximately 14%
[16]. Given its potential tumor-suppressor capabilities, we eval-
uated IRF-1 expression and IFN-g responsiveness in three EA
cell lines and examined the effects of IRF-1 overexpression on
EA cell viability and tumor growth rates. Our findings demon-
strate that Ad-IRF-1 infection of EA cells induces apoptosis
in vitro and modestly inhibits tumor growth rates in vivo.
Materials and Methods
Cell Lines
Three human EA-derived cell lines (Seg-1, Bic-1, and Flo-1)
have been previously described [17]. Seg-1 was maintained in
RPMI 1640, and Bic-1 and Flo-1 were maintained in DMEM
(BioWhittaker, Walkersville, MD). Media were supplemented
with 10% fetal bovine serum (Atlanta Biologicals, Norcross,
GA), 1% penicillin/streptomycin, and 1% L-glutamine (Invitro-
gen, Carlsbad, CA), and cells were propagated in a humidified
environment at 37jC with 5% CO2.
Antibodies and Reagents
For immunoblotting, anti-human IRF-1, anti-murine IRF-1,
anti-Fas (C-20), anti–phospho extracellular regulated kinase
(ERK), anti-ERK, and anti–IRF-2 antibodies were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-
survivin antibody and human IFN-g were purchased from R&D
Systems (Minneapolis, MN). Anti-Fas antibody Apo 1-1 was
purchased from Kamiya Biomedical Co. (Seattle, WA). Second-
ary antibodies were purchased from Jackson Immunoresearch,
Inc. (West Grove, PA). zVad was purchased from Promega
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(Madison, WI). The ERK inhibitor PD98059 (50 mM) was
purchased from Calbiochem (La Jolla, CA). The c-Met–
specific inhibitor PHA665752 (200 nM) [18] was provided by
James Christensen (Pfizer, San Francisco, CA).
Ad-IRF-1 Construction and Infection
The Ad-IRF-1 construct has previously been described
[19]. Cells were infected for 4 hours at 37jC in 5% CO2 with
either empty adenovirus (Ad-C5) or murine IRF-1 construct
(Ad-IRF-1). Optimal multiplicity of infection (MOI) was deter-
mined by using Ad-eGFP and bymeasuring the percentage of
fluorescent cells 24 and 48 hours later. Approximately 90%
transduction was achieved with MOI = 100 in Seg-1 and Flo-1
and with MOI = 500 in Bic-1.
Immunoblotting
Cellular protein was extracted using lysis buffer (Cell Sig-
naling Technology, Beverly, MA) containing 1 mM phenyl-
methlsulfonylfluoride (Sigma-Aldrich Corp., Atlanta, GA) and
quantified using BCA protein assay kit (Pierce, Rockford, IL).
Proteins were resolved using sodium dodecyl sulfate (SDS)
polyacrylamide gels and subsequently transferred to nitro-
cellulose membranes (Bio-Rad, Hercules, CA). Membranes
were blocked in 5% milk solution, incubated with primary anti-
body, washed, and incubated with HRP-conjugated secondary
antibody. Immunoreactivity was detected using Supersignal
West PicoChemiluminescent Substrate (Pierce) andX-ray film
(Eastman Kodak, Rochester, NY). Blots were stripped with 2%
SDS, 100 mM b-mercaptoethanol, and 62.5 mM Tris (pH 6.8)
for 20 minutes at 60jC and reprobed with anti–b-actin (Sigma-
Aldrich Corp.).
FACScan Analysis of Apoptosis and Fas Expression
Cells were treated with a supraphysiologic dose of human
IFN-g (1,000 U/ml) or infected with Ad-C5 or Ad-IRF-1, as
above. For apoptosis studies, the pan-caspase inhibitor zVad
(50 mM) was added to the cultures following a 4-hour infec-
tion period, and the cells were propagated for 36 hours,
harvested, and stained using Annexin V (AV)-fluorescein iso-
thiocyanate (FITC) apoptosis detection kit (BD Biosciences,
San Diego, CA). For Fas cell surface expression, cells were
collected and rinsed at various time points (0.5–36 hours), as
above. Cells were labeled with Apo 1-1 anti-Fas antibody and
FITC-conjugated secondary antibody. Apoptosis and Fas ex-
pressions were assessed by flow cytometry using a Becton
Dickinson FACSort (San Jose, CA).
In Vivo Treatment of Tumor-Bearing Mice
All animal studies were conducted in accordance with the
Council on Animal Care at the University of Pittsburgh (Pitts-
burgh, PA). Seg-1 cells growing in log phase were resus-
pended in Hanks balanced salt solution, and 2.5  106 cells
were inoculated subcutaneously in the right flank of 4- to
6-week-old male nude nu/nu-nubr mice (Charles River Lab-
oratories, Wilmington, MA). When tumors reached 30 to
35 mm3 by perpendicular measurements, mice were random-
ized (n = 5 mice per group) and received intratumoral injection
of 6  108 plaque-forming units of Ad-IRF-1, Ad-C5, or PBS
(in a total volume of 30 ml) every 4 days for a total of three
treatments. Tumor growth was followed by serial measure-
ments of perpendicular diameters using digital calipers. Tumor
volumes were calculated according to the formula: 0.52 
(width)2  length [20]. Animals that were moribund or had
tumors greater than approximately 4189mm3were sacrificed.
Statistical Analysis
In vivo tumor growth rates for each treatment group were
compared by estimating tumor growth curves (after regress-
ing log-transformed tumor volumes on each day’s tumor vol-
ume measurement) and by testing differences in regression
coefficients. A mixed-model approach [21], which represents
individual mice as random effects and accounts for between-
and within-mouse variations, was used. A likelihood ratio
test was constructed to determine the appropriate choice for
model parameters. In addition to model-based results, differ-
ences in means on day 10 (as a check for adequacy of ran-
domization) and day 26 (final day of tumor measurements)
were tested with Kruskal-Wallis test [22].
Results
IFN-g Signaling Pathway Is Intact in EA Cells
We began our study by characterizing IRF-1 expression
and the IFN-g signaling pathway in three EA cell lines. By im-
munoblot analysis, Bic-1, Seg-1, and Flo-1 cells lack de-
tectable IRF-1 protein in the absence of IFN-g stimulation
(Figure 1A). All three EA cell lines express IRF-1 protein fol-
lowing IFN-g stimulation, with peak levels observed at
24 hours in the Seg-1 and Flo-1 cell lines and at 48 hours
in the Bic-1 cell line. IRF-1 protein expression persists for
72 hours following IFN-g stimulation in all of the EA cell lines,
except for Seg-1, where IRF-1 protein is undetectable at
48 hours. Obviousmorphologic changes or signs of cell death
were not seen, even after 72 hours of stimulation with IFN-g
(data not shown). We concluded that IRF-1 protein is ex-
pressed in all three EA cell lines following IFN-g stimulation,
suggesting that IRF-1 is not lost and that the IFN-g signaling
pathway is intact.
Next, we overexpressed IRF-1 in the EA cell lines using
an adenoviral IRF-1 vector, which was previously shown to
result in the production of murine IRF-1 that is functional in
human cells [19]. Figure 1B demonstrates that IRF-1 protein
was expressed in all three EA cell lines 24 hours following
infection with Ad-IRF-1. Infection with an empty adenovirus
(Ad-C5) did not induce IRF-1 expression. Near-complete loss
of cultures was observed following Ad-IRF-1 infection, sug-
gesting treatment-induced cell death (data not shown). These
results demonstrate that Ad-IRF-1 infection results in abun-
dant IRF-1 protein expression. In contrast to IFN-g treatment,
Ad-IRF-1 infection appears to induce extensive cell death in
these EA cell lines.
Ad-IRF-1 Infection Induces Apoptosis in EA Cells
IRF-1 has previously been shown to induce apoptosis
in other cell types [4,19,23,24]. Because Ad-IRF-1 infection
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caused near-complete loss of cultures, we hypothesized that
Ad-IRF-1 infection induced apoptosis. Thirty-six hours fol-
lowing infection with either Ad-C5 or Ad-IRF-1, cell viability
was analyzed using flow cytometry. We observed a sub-
stantial increase in positively stained cell populations follow-
ing Ad-IRF-1 infection, but not following IFN-g treatment
(Figure 2A). This effect was not observed in the cultures
treated with equivalent MOI of Ad-C5, suggesting that it is
due to IRF-1 expression and not nonspecific viral-induced
necrosis. This effect was seen within 24 hours of infection,
and the maximum percentage of nonviable cells was ob-
served at 48 hours in all three EA cell lines. Pretreatment with
the pan-caspase inhibitor zVad rescued a variable percent-
age of the cells from Ad-IRF-1– induced cell death (Figure 2,
A and B), suggesting that Ad-IRF-1– induced cell death is, in
large part, due to apoptosis. This was further supported by
demonstrations of PARP cleavage and induced caspase-3
activity (data not shown). Taken together, these findings show
that Ad-IRF-1 infection (but not IFN-g treatment) induces
significant apoptosis in EA cells.
Figure 1. The IFN-c signaling pathway is intact in EA cells. (A) Three EA cell lines (Seg-1, Bic-1, and Flo-1) were cultured for 24 to 72 hours in the presence or
absence of human IFN-c (1,000 U/ml). IFN-c induced human IRF-1 (50 kDa) expression in all three EA cell lines. The smaller band seen in the untreated Bic-1 cell
line is inconsistently observed in all three EA cell lines regardless of treatment and is suspected to represent nonspecific immunoreactivity. (B) Seg-1, Bic-1, and
Flo-1 EA cell lines were infected at a range of MOI with either an empty adenoviral vector (Ad-W5) or Ad-IRF-1. Ad-IRF-1 (but not Ad-W5) resulted in an MOI-
dependent increase in murine IRF-1 (45 kDa) expression.
Figure 2. Ad-IRF-1 infection induces apoptosis in EA cells. (A) FACScan analysis of AV- and propidium iodide (PI) – stained cells 36 hours following treatment with
a supraphysiologic dose (1,000 U/ml) of IFN-c or infection with either empty adenovirus (Ad-W5) or Ad-IRF-1. Positive staining for AV suggests apoptosis (right
lower quadrant). Positive staining for PI suggests loss of membrane integrity late in apoptosis (right upper quadrant) or necrosis (left upper quadrant). Neither
treatment with IFN-c nor infection with Ad-W5 resulted in significant apoptosis. Ad-IRF-1 infection caused cell death in all three EA cell lines, which was largely
prevented by pretreatment with the pan-caspase inhibitor zVad, suggesting that Ad-IRF-1 induces apoptosis. (B) Percentage of viable cells corresponds to the
negatively stained population (left lower quadrant). Percent zVad rescue represents the difference between the viable populations following infection with Ad-IRF-1
in the presence or absence of zVad.
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EA Cells Produce Functional IRF-1 Following
IFN-g Stimulation
Several key mediators of apoptosis, including the death
receptor Fas, the IRF-1 antagonist IRF-2, and the inhibitor-
of-apoptosis protein survivin, are known targets of IFN-g
signaling [4,25–27]. Because Ad-IRF-1 infection (but not
IFN-g treatment) induced apoptosis, we hypothesized
that modulation of these mediators by Ad-IRF-1 and IFN-g
differed. Cell surface Fas expression increased to a similar
degree following treatment with both IFN-g and Ad-IRF-1
(Figure 3A). This effect was evident by 12 hours and persisted
for 36 hours in IFN-g–treated (but not Ad-IRF-1–infected)
Figure 3. Effects of IFN-c stimulation compared to Ad-IRF-1 infection. (A) FACScan and (B) immunoblotting of Fas expression in Seg-1 cells following treatment
with either IFN-c (1,000 U/ml), Ad-W5, or Ad-IRF-1. Although Fas protein increased following all three treatments, only IFN-c and Ad-IRF-1 resulted in increased cell
surface expression of Fas (shaded histograms represent controls; 24-hour time point shown). (C) Immunoblot for IRF-2 and survivin 36 hours following treatment
with IFN-c, Ad-W5, or Ad-IRF-1. Neither treatment altered IRF-2 levels. Survivin levels decreased modestly following Ad-IRF-1 infection (but not IFN-c treatment) in
Bic-1 and Flo-1 cells, whereas survivin decreased following IFN-c treatment (but not Ad-IRF-1 infection) in Seg-1 cells. (D) ERK2 is phosphorylated (pErk) in Seg-1
cells following treatment with both IFN-c and Ad-IRF-1. Total ERK levels were unchanged. (E) FACScan analysis of AV- and PI-labeled Seg-1 cells treated with
IFN-c for 72 hours in the presence or absence of the ERK inhibitor PD98059 (50 M) or the c-Met inhibitor PHA665752 (200 nM). Neither ERK inhibition nor c-Met
inhibition sensitized the cells to IFN-c.
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cells. Fas protein increased following all treatments, including
Ad-C5 (Figure 3B), suggesting that increased Fas cell surface
expression is not due to increased protein synthesis alone.
Neither IFN-g treatment nor Ad-IRF-1 infection altered IRF-2
expression (Figure 3C). Survivin levels consistently de-
creased following IFN-g treatment, but not following Ad-IRF-
1 infection in Seg-1 cells, whereas the converse was true in
Bic-1 and Flo-1 cells (Figure 3C), suggesting that modula-
tion of survivin is cell line–specific and that decreased sur-
vivin levels alone are not sufficient to induce apoptosis in
Seg-1 cells. We concluded that the discrepancy between the
ability of IFN-g and Ad-IRF-1 to induce apoptosis in these EA
cells is not solely related to differential modulation of these
apoptotic mediators.
IFN-g stimulation also activates pathways that antagonize
apoptosis, including ERK2 [28] and c-Met [29,30], and we
have previously shown universal overexpression of the hepa-
tocyte growth factor receptor c-Met in EA [31]. We hypothe-
sized that IFN-g treatment (but not Ad-IRF-1 infection) would
activate ERK2 and c-Met signaling. Interestingly, both IFN-g
and Ad-IRF-1 resulted in varying degrees of ERK2 phos-
phorylation (Figure 3D), but inhibition of ERK2 combined with
IFN-g treatment did not induce apoptosis (Figure 3E). Like-
wise, inhibition of c-Met with PHA665752 did not sensitize
these EA cells to IFN-g (Figure 3E). We concluded that IRF-1
at least partially modulates IFN-g– induced activation of
ERK2, but that neither ERK2 nor c-Met signaling regulates
IFN-g sensitivity in these EA cells. Taken together, these find-
ings suggest that IRF-1 produced following IFN-g stimulation
is functional and that activation of an undefined pathway
may mediate IFN-g responsiveness in these EA cells.
In Vivo Administration of Ad-IRF-1 Decreases
Tumor Growth Rates
Given our in vitro findings demonstrating that IRF-1 in-
duces apoptosis in EA cells, we hypothesized that Ad-IRF-1
injection into established flank tumors in nude mice would
result in tumor regression. Figure 4 demonstrates observed
(dotted) and predicted (solid) growth rates of tumors mea-
sured every 3 to 4 days following treatment. There were no
differences in mean tumor volumes on the first day of tumor
measurements (day 10; P = .763) or on the final day of mea-
surement (day 26; P = .618). A mixed quadratic model was
fitted to log-transformed tumor volumes. A test for equality of
slopes revealed modest evidence of interaction between
treatment groups (PBS, Ad-C5, and Ad-IRF-1) and day of
measurement (P = .062), suggesting unequal regression
coefficients and differential tumor growth rates. The apparent
difference in growth rate may be attributed to a decrease in
growth rate for Ad-IRF-1–treated mice. No negative effects
of the treatment, such as local skin ulcers, reduction in ac-
tivity, or decreased enteral intake, were observed in any of
the mice. Tumors were resected at the conclusion of the
experiment and analyzed for IRF-1 expression by immuno-
staining. IRF-1 immunoreactivity was not observed in either
treatment group (data not shown). This was expected given
the known rapid clearance of IRF-1–transduced cells in vivo
[27]. These results demonstrate that intratumoral delivery of
Ad-IRF-1 modestly inhibits tumor growth rates in an in vivo
model of EA, but does not lead to tumor regression.
Discussion
Our study is one of the few to investigate the role of IRF-1 in
the pathophysiology and treatment of gastrointestinal malig-
nancies and is the first to examine its role in EA. We have
shown that IRF-1 overexpression induces apoptosis in EA
cells in vitro and inhibits EA tumor growth rates in vivo. Little,
if any, basal IRF-1 protein was detected in these EA cells, but
all three cell lines expressed IRF-1 following IFN-g stimula-
tion, suggesting that IRF-1 is not lost and that the IFN-g
signaling pathway is functional. A supraphysiologic dose of
IFN-g did not induce cell death, yet Ad-IRF-1 infection in-
duced extensive apoptosis in all three cell lines. Additionally,
in vivo administration of Ad-IRF-1 in a murine model of EA re-
sulted in decreased rates of tumor growth relative to controls.
Taken together, these findings support the use of strategies
to augment IRF-1 expression as a therapeutic option for EA.
Studies in breast cancer have shown that IRF-1 expres-
sion is reduced or lost both in vitro and in vivo [32]. Similarly,
we observed little, if any, IRF-1 expression in unstimulatedEA
cells. Ad-IRF-1 infection generates high levels of functional
IRF-1 protein and induces apoptosis in breast cancer [19,27]
and other neoplasms [2]. Indeed, Ad-IRF-1 infection induced
substantial apoptosis in vitro in two of the EA cell lines (Seg-1
and Flo-1), with lesser effects seen in Bic-1 cells. This finding
may be attributable to reduced postinfection IRF-1 production
in Bic-1 cells relative to Seg-1 and Flo-1 cells (Figure 1B). The
possibility that Bic-1 cells are less sensitive to the effects
of Ad-IRF-1, however, must be considered. Importantly, this
Ad-IRF-1 induction of apoptosis is in contrast to our previous
experience with other virally introduced proteins such as Ad-
p53 that have not resulted in the induction of apoptosis [33].
Figure 4. Differential growth rate of tumors in vivo derived from Seg-1 cells
following intratumoral injection with PBS, Ad-W5, or Ad-IRF-1. The graph
shows observed and predicted tumor volumes of five mice randomly assigned
to treatment with PBS, control vector (Ad-W5), or Ad-IRF-1. The dotted lines
are the observed tumor volumes; the solid lines are the predicted tumor vol-
umes based on the fitted model. Ad-IRF-1 treatment modestly inhibited tumor
growth rates ( P = 0.06) but did not result in regression.
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Although IFN-g treatment alone induces apoptosis in some
carcinoma models [12,34], resistance to IFN-g is common.
Levels of IRF-1 may determine whether IFN-g induces apop-
tosis, and the amount of IRF-1 produced following IFN-g
treatment may be regulated by the amount of IFN-g recep-
tor (IFNGR) present [35,36] or the rapid downregulation of
IFNGR. Lack of IRF-1 expression in Seg-1 cells 48 hours
following IFN-g stimulation (Figure 1A) suggests that rapid
downregulation of the IFNGR may occur in this cell line. Al-
though it remains possible that Ad-IRF-1 infection generates
more IRF-1 than IFN-g treatment, we did not observe a sig-
nificant difference in the transduction of known targets of IRF-1
(i.e., Fas) between the two treatments.
IFN-g stimulation is also known to generate antagonistic
effects simultaneous to those of IRF-1 (i.e., IRF-2), or to ac-
tivate pathways that oppose IRF-1 function (i.e., c-Met and
ERK2). IRF-2 is a putative oncogene and antagonizes IRF-1
by competing for the sameDNA-binding sites [37]. All three of
our EA cell lines abundantly express IRF-2 (Figure 3C); al-
though IRF-2 levels were not altered by IFN-g or Ad-IRF-1,
overexpression of IRF-2 may inhibit responsiveness to IFN-g
in these cell lines. c-Met and ERK activation typically results
in cell proliferation and resistance to apoptosis [38,39], al-
though our observations fail to support a significant role for
c-Met or ERK in the regulation of IFN-g sensitivity. Collectively,
our data suggest that other signaling events downstream of
the IFNGR may counter IFN-g signaling through STAT-1.
Although inhibition of tumor growth rates following Ad-IRF-
1 treatment in vivo did not reach statistical significance, a
trend was apparent. Although repetition of in vivo experi-
mentswithmore animals, larger doses of Ad-IRF-1, or smaller
tumor burdens at the onset may have produced statistically
significant results, we have not pursued this, as our current
data suggest that replication-deficient adenoviral delivery
through direct tumor injection will not produce an adequate
clinical response to an established tumor [40]. Rather, we con-
clude that alternative viral delivery strategies need to be con-
sidered (i.e. retrovirus).
In summary, our study is the first to investigate the role of
IRF-1 in the pathophysiology and treatment of EA. We have
shown that IRF-1 overexpression induces the apoptosis of EA
cells in vitro and modestly inhibits tumor growth rates in vivo.
Taken together, our findings suggest that strategies designed
to augment IRF-1 expression may be useful in the manage-
ment of EA.
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